FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205691653> ?p ?o ?g. }

• W4205691653 endingPage "102093" @default.
• W4205691653 startingPage "102093" @default.
• W4205691653 abstract "Population trends in PSA testing and prostate cancer incidence do not perfectly correspond. We aimed to better understand relationships between trends in PSA testing, prostate cancer incidence and mortality in Australia and factors that influence them.We calculated and described standardised time trends in PSA tests, prostate biopsies, treatment of benign prostatic hypertrophy (BPH) and prostate cancer incidence and mortality in Australia in men aged 45-74, 75-84, and 85 + years.PSA testing increased from its introduction in 1989 to a peak in 2008 before declining in men aged 45-84 years. Prostate biopsies and cancer incidence fell from 1995 to 2000 in parallel with decrease in trans-urethral resections of the prostate (TURP) and, latterly, changes in pharmaceutical management of BPH. After 2000, changes in biopsies and incidence paralleled changes in PSA screening in men 45-84 years, while in men ≥85 years biopsy rates stabilised, and incidence fell. Prostate cancer mortality in men aged 45-74 years remained low throughout. Mortality in men 75-84 years gradually increased until mid 1990s, then gradually decreased. Mortality in men ≥ 85 years increased until mid 1990s, then stabilised.Age specific prostate cancer incidence largely mirrors PSA testing rates. Most deviation from this pattern may be explained by less use of TURP in management of BPH and consequent less incidental cancer detection in TURP tissue specimens. Mortality from prostate cancer initially rose and then fell below what it was when PSA testing began. Its initial rise and fall may be explained by a possible initial tendency to over-attribute deaths of uncertain cause in older men with a diagnosis of prostate cancer to prostate cancer. Decreases in mortality rates were many fold smaller than the increases in incidence, suggesting substantial overdiagnosis of prostate cancer after introduction of PSA testing." @default.
• W4205691653 created "2022-01-25" @default.
• W4205691653 creator A5004538875 @default.
• W4205691653 creator A5005751643 @default.
• W4205691653 creator A5009613327 @default.
• W4205691653 creator A5021292619 @default.
• W4205691653 creator A5031546034 @default.
• W4205691653 creator A5072652828 @default.
• W4205691653 creator A5078264584 @default.
• W4205691653 date "2022-04-01" @default.
• W4205691653 modified "2023-10-14" @default.
• W4205691653 title "Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis" @default.
• W4205691653 cites W1485235179 @default.
• W4205691653 cites W1495104903 @default.
• W4205691653 cites W1904441683 @default.
• W4205691653 cites W1972513573 @default.
• W4205691653 cites W1988696103 @default.
• W4205691653 cites W1996595151 @default.
• W4205691653 cites W2013998071 @default.
• W4205691653 cites W2075681175 @default.
• W4205691653 cites W2095761465 @default.
• W4205691653 cites W2096619957 @default.
• W4205691653 cites W2116777253 @default.
• W4205691653 cites W2119391023 @default.
• W4205691653 cites W2121103668 @default.
• W4205691653 cites W2125837480 @default.
• W4205691653 cites W2132528779 @default.
• W4205691653 cites W2134793522 @default.
• W4205691653 cites W2146822966 @default.
• W4205691653 cites W2146920094 @default.
• W4205691653 cites W2150679001 @default.
• W4205691653 cites W2152001676 @default.
• W4205691653 cites W2154205824 @default.
• W4205691653 cites W2158140837 @default.
• W4205691653 cites W2163098725 @default.
• W4205691653 cites W2163979886 @default.
• W4205691653 cites W2168133848 @default.
• W4205691653 cites W2184606342 @default.
• W4205691653 cites W2250370026 @default.
• W4205691653 cites W2318326885 @default.
• W4205691653 cites W2410876732 @default.
• W4205691653 cites W2416249908 @default.
• W4205691653 cites W2419165354 @default.
• W4205691653 cites W2511731321 @default.
• W4205691653 cites W2806550451 @default.
• W4205691653 cites W2895215197 @default.
• W4205691653 cites W4242570784 @default.
• W4205691653 cites W60325291 @default.
• W4205691653 doi "https://doi.org/10.1016/j.canep.2021.102093" @default.
• W4205691653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35026706" @default.
• W4205691653 hasPublicationYear "2022" @default.
• W4205691653 type Work @default.
• W4205691653 citedByCount "12" @default.
• W4205691653 countsByYear W42056916532022 @default.
• W4205691653 countsByYear W42056916532023 @default.
• W4205691653 crossrefType "journal-article" @default.
• W4205691653 hasAuthorship W4205691653A5004538875 @default.
• W4205691653 hasAuthorship W4205691653A5005751643 @default.
• W4205691653 hasAuthorship W4205691653A5009613327 @default.
• W4205691653 hasAuthorship W4205691653A5021292619 @default.
• W4205691653 hasAuthorship W4205691653A5031546034 @default.
• W4205691653 hasAuthorship W4205691653A5072652828 @default.
• W4205691653 hasAuthorship W4205691653A5078264584 @default.
• W4205691653 hasConcept C120665830 @default.
• W4205691653 hasConcept C121332964 @default.
• W4205691653 hasConcept C121608353 @default.
• W4205691653 hasConcept C126322002 @default.
• W4205691653 hasConcept C126894567 @default.
• W4205691653 hasConcept C143998085 @default.
• W4205691653 hasConcept C2775941076 @default.
• W4205691653 hasConcept C2776235491 @default.
• W4205691653 hasConcept C2780192828 @default.
• W4205691653 hasConcept C2780768273 @default.
• W4205691653 hasConcept C2781217009 @default.
• W4205691653 hasConcept C2781406297 @default.
• W4205691653 hasConcept C29456083 @default.
• W4205691653 hasConcept C61511704 @default.
• W4205691653 hasConcept C71924100 @default.
• W4205691653 hasConceptScore W4205691653C120665830 @default.
• W4205691653 hasConceptScore W4205691653C121332964 @default.
• W4205691653 hasConceptScore W4205691653C121608353 @default.
• W4205691653 hasConceptScore W4205691653C126322002 @default.
• W4205691653 hasConceptScore W4205691653C126894567 @default.
• W4205691653 hasConceptScore W4205691653C143998085 @default.
• W4205691653 hasConceptScore W4205691653C2775941076 @default.
• W4205691653 hasConceptScore W4205691653C2776235491 @default.
• W4205691653 hasConceptScore W4205691653C2780192828 @default.
• W4205691653 hasConceptScore W4205691653C2780768273 @default.
• W4205691653 hasConceptScore W4205691653C2781217009 @default.
• W4205691653 hasConceptScore W4205691653C2781406297 @default.
• W4205691653 hasConceptScore W4205691653C29456083 @default.
• W4205691653 hasConceptScore W4205691653C61511704 @default.
• W4205691653 hasConceptScore W4205691653C71924100 @default.
• W4205691653 hasLocation W42056916531 @default.
• W4205691653 hasLocation W42056916532 @default.
• W4205691653 hasOpenAccess W4205691653 @default.
• W4205691653 hasPrimaryLocation W42056916531 @default.
• W4205691653 hasRelatedWork W1979374145 @default.

• next